丁螺环酮治疗焦虑症前后脑内神经递质的变化及意义

Changes and Its Significant of Cerebral Neurotransmitters:Before and after Treatment with Buspar for Anxiety

目的:用脑电超慢涨落分析(ET)仪检测焦虑症患者治疗前后脑内神经递质的变化。方法:对符合入组标准的43例患者治疗前后用脑电超慢涨落分析(ET)仪对神经递质含量进行检测。结果:焦虑症组GABA、DA分值低于正常对照组(P<0.01);5-HT及NE分值高于正常对照组,(P<0.01),Ach分值与对照组相比基本一致,差别无显著性(P>0.05)。焦虑症组治疗后GABA较治疗前升高,差别具有显著性(P<0.05);5-HT较治疗前降低,差别具有显著性(P<0.05);DA、NE、Ach差别无显著性(P>0.05)。结论:ET检测脑内神经递质在焦虑症中随疾病恢复的动态变化,可作为判断疗效、治疗安全性的依据。

Objective：To observe the changes of cerebral neurotransmitters in treatment of anxiety with Bus- par. Methods： All subjects were assigned to the anxiety group （n = 43 ）, they were eligible for standard anxiety and treated with Buspar, 5mg/d to 40mg/d for six weeks according to efficacy and side effects, and the healthy control group （ n = 30）. The level of neurotransmitters, such as 5 - HT, norepinephrine （ NE）, dopamine （DA） and GABA, were measured in both groups before and after management using encephalofluctuogram technology （ ET）. Results： Compared with the control group, the levels of 5 - HT and NE were increased （ P 〈 0.01 ） ; the levels GABA and DA were decreased （P 〈0.01 ）. The level of GABA in anxiety group after treatment was higher than that before treatment （P 〈 0.05 ） ; level of 5 - HT, by contrast, was lower （ P 〈 0.05 ）, no changes of level of DA, NE and Ach （ P 〉 0.05）. Conclusions： Measure of cerebral neurotransmitters by ET could be a basis for efficiency and safety of treatment for anxiety.